Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic
Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic
Adenovirus vectors deliver the genetic instructions for SARS-CoV-2 antigens directly into patients’ cells, provoking a robust immune response. But will pre-existing immunity from common colds take them down?
Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic
Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic

Adenovirus vectors deliver the genetic instructions for SARS-CoV-2 antigens directly into patients’ cells, provoking a robust immune response. But will pre-existing immunity from common colds take them down?

Adenovirus vectors deliver the genetic instructions for SARS-CoV-2 antigens directly into patients’ cells, provoking a robust immune response. But will pre-existing immunity from common colds take them down?

spike protein
SARS-CoV-2 Antibody Durability
SARS-CoV-2 Antibody Durability
The Scientist Creative Services Team | Oct 2, 2020
Experts will discuss their research on SARS-CoV-2 antibody persistence and immune memory in recovered COVID-19 patients and the implications for protective immunity.
Modeling Study Flags Species Susceptible to SARS-CoV-2
Modeling Study Flags Species Susceptible to SARS-CoV-2
Anthony King | Aug 26, 2020
Some critically endangered animals are on the list.
Differences in Antibody Responses Linked to COVID-19 Outcomes
Differences in Antibody Responses Linked to COVID-19 Outcomes
Katarina Zimmer | Aug 18, 2020
In a small study of patients hospitalized due to SARS-CoV-2 infection, researchers report distinct early differences between the antibody responses of patients who recovered and those who died, possibly paving the way for a tool to predict disease prognosis.
First Antibody Trial Launched in COVID-19 Patients
First Antibody Trial Launched in COVID-19 Patients
Katarina Zimmer | Jun 2, 2020
In record time, scientists have gone from harvesting antibodies against SARS-CoV-2 from survivors of coronavirus infections to testing the antibodies’ safety as a drug in humans.
COVID-19 Vaccine Researchers Mindful of Immune Enhancement
COVID-19 Vaccine Researchers Mindful of Immune Enhancement
Katarina Zimmer | May 26, 2020
There is no evidence that any of the coronavirus vaccines in development worsen a coronavirus infection rather than confer immunity to it, but the phenomenon is something scientists are closely monitoring.
Moderna’s Coronavirus Vaccine Spurs Immune Response: Early Data
Moderna’s Coronavirus Vaccine Spurs Immune Response: Early Data
Ashley Yeager | May 18, 2020
A clinical trial of the shot in eight volunteers suggests that it is safe and that it generates antibodies that neutralize SARS-CoV-2, but further testing is needed, scientists say.
Crowdsourced Protein Simulation Exceeds Supercomputers’ Power
Crowdsourced Protein Simulation Exceeds Supercomputers’ Power
Shawna Williams | Apr 15, 2020
Folding@Home, currently focused on deciphering the workings of SARS-CoV-2, is the first project to have exascale-level computational muscle.
Scientists Scan for Weaknesses in the SARS-CoV-2 Spike Protein
Scientists Scan for Weaknesses in the SARS-CoV-2 Spike Protein
Chris Baraniuk | Apr 9, 2020
The virus’s tool for prying open host cells is coated in a protective armor of sugar—but gaps may offer vulnerability to disruption by antibodies.
Novel Virus Entry Portal Found
Novel Virus Entry Portal Found
Sabrina Richards | Mar 13, 2013
Researchers identify the target protein of a recently discovered human coronavirus, shedding light on infection and possible interspecies spread.